GeoVax to Present at the 36th Annual Roth Conference
12 Marzo 2024 - 2:00PM
via NewMediaWire --
GeoVax Labs, Inc. (Nasdaq: GOVX), a
biotechnology company developing immunotherapies and vaccines
against cancers and infectious diseases, announced today that its
Chairman and CEO, David Dodd, will present at the 36th Annual Roth
Conference, taking place in Dana Point, CA on March 17-19, 2024.
Presentation Details:
Presenter: David Dodd,
Chairman & CEODate/Time: March 18, 2024,
2:30 pm PTLocation: Dana Point,
CAWebcast Link: Roth Conference Webcast
The Company will also host in-person investor
meetings. Institutional investors wishing to attend the
conference and schedule meetings with GeoVax leadership should
contact their Roth MKM representative.
About GeoVaxGeoVax Labs, Inc. is a
clinical-stage biotechnology company developing novel therapies and
vaccines for solid tumor cancers and many of the world’s most
threatening infectious diseases. The company’s lead program in
oncology is a novel oncolytic solid tumor gene-directed therapy,
Gedeptin®, presently in a multicenter Phase 1/2 clinical trial for
advanced head and neck cancers. GeoVax’s lead infectious disease
candidate is GEO-CM04S1, a next-generation Covid-19 vaccine
targeting high-risk immunocompromised patient populations.
Currently in three Phase 2 clinical trials, GEO-CM04S1 is being
evaluated as a primary vaccine for immunocompromised patients such
as those suffering from hematologic cancers and other patient
populations for whom the current authorized Covid-19 vaccines are
insufficient, and as a booster vaccine in patients with chronic
lymphocytic leukemia (CLL). In addition, GEO-CM04S1 is in a Phase 2
clinical trial evaluating the vaccine as a more robust, durable
Covid-19 booster among healthy patients who previously received the
mRNA vaccines. GeoVax has a leadership team who have driven
significant value creation across multiple life science companies
over the past several decades. For more information, visit our
website: www.geovax.com.
Company
Contact: |
|
Investor
Relations Contact: |
|
Media
Contact: |
info@geovax.com |
|
paige.kelly@sternir.com |
|
sr@roberts-communications.com |
678-384-7220 |
|
212-698-8699 |
|
202-779-0929 |
Grafico Azioni GeoVax Labs (NASDAQ:GOVX)
Storico
Da Gen 2025 a Feb 2025
Grafico Azioni GeoVax Labs (NASDAQ:GOVX)
Storico
Da Feb 2024 a Feb 2025